s in patients with cystic fibrosis, chronic pancreatitis, and various other conditions. Synthroid: Synthroid is used in the treatment of hypothyroidism. The company has the rights to sell AndroGel, Creon, and Synthroid in the United States. Endocrinology Products Lupron (also marketed as Lucrin and Lupron Depot) is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month, and six-month intramuscular injection. Other Products The company’s other products include the following: Duopa and Duodopa: The company’s levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States. Anesthesia Products: Sevoflurane (sold under the trademarks Ultane and Sevorane) is an anesthesia product that the company sells worldwide for human use. Dyslipidemia Products: The company’s dyslipidemia products (TriCor, Trilipix, Niaspan, Simcor, and Advicor) address the range of metabolic conditions characterized by high cholesterol and/or high triglycerides. Zemplar: Zemplar is a product sold worldwide for the treatment of secondary hyperparathyroidism associated with Stage 3, 4, and 5 chronic kidney disease. Marketing, Sales, and Distribution The company utilizes a combination of commercial resources, regional commercial resources, and distributorships to market, sell, and distribute its products worldwide. The company directs its primary marketing efforts toward securing the prescription, or recommendation, of its brand of products by physicians, key opinion leaders, and other health care providers. Managed care providers (health maintenance organizations and pharmacy benefit managers), hospitals, and state and federal government agencies (the United States Department of Veterans Affairs and the United States Department of Defense) are also primary customers. The company also markets directly to consumers themselves, although in the United States all of the company's products must be sold pursuant to a prescription. In 2014, the company’s products were sold in approximately 170 countries. The company’s products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from company-owned distribution centers and public warehouses. In the United States, the company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies and patients. In 2014, three wholesale distributors (McKesson Corporation; Cardinal Health, Inc.; and AmerisourceBergen Corporation) accounted for all of the company’s sales in the United States. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Research and Development Activities The company spent approximately $3.3 billion on research to discover and develop new products, indications, and processes and to improve existing products and processes in 2014. Regulation The company’s operations are affected by trade regulations in various countries that limit the import of raw materials and finished products and by laws and regulations that seek to prevent corruption and bribery in the marketplace (including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, which provide guidance on corporate interactions with government officials) and require safeguards for the protection of personal data. The company is also subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-kickback and false claims laws in the United States. History AbbVie Inc. was incorporated in Delaware in 2012.
abbvie inc (ABBV:New York)
1 North Waukegan Road
North Chicago, IL 60064
|Abbott Laboratories||$48.32 USD||-0.14|
|Amgen Inc||$167.91 USD||-1.26|
|Bristol-Myers Squibb Co||$65.80 USD||-0.20|
|Eli Lilly & Co||$71.58 USD||-0.82|
|Medtronic PLC||$77.61 USD||-0.89|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.